NuVasive | Des Atouts



Des Atouts Changement Date
Abbott USD 86.71B 2.53B 2025-12
AtriCure USD 654.18M 18.74M 2025-12
Baxter International USD 20.06B 1.01B 2025-12
Becton, Dickinson and Co. USD 54.84B 484M 2025-12
Boston Scientific USD 43.67B 966M 2025-12
Cooper Companies USD 12.39B 18.1M 2025-09
Dexcom USD 6.34B 1.16B 2025-12
Edwards Lifesciences USD 13.27B 216.5M 2025-09
Globus Medical USD 5.1B 134.55M 2025-09
Haemonetics USD 2.49B 48.73M 2025-12
Hologic USD 9.18B 165.8M 2025-12
Inogen USD 307.01M 5.03M 2025-09
Insulet USD 3.19B 161.1M 2025-12
Integra LifeSciences USD 3.65B 21.45M 2025-09
Intuitive Surgical USD 20.46B 1.11B 2025-12
J&J USD 199.21B 6.39B 2025-12
Medtronic USD 91.35B 374M 2025-09
Merit Medical Systems USD 2.63B 44.95M 2025-09
Orthofix International USD 832.61M 4.55M 2025-09
Stryker USD 47.84B 787M 2025-12
Tandem Diabetes Care USD 881.11M 6.46M 2025-12
Teleflex USD 7.87B 496.72M 2025-09
Zimmer Biomet Holdings USD 23.09B 396.3M 2025-12


NuVasive Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.